Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: WhatsUpWithThat who wrote (95346)	9/10/1999 2:55:00 PM
From: kumqwatt	Respond to of 119973

BIOM running on : The Drug and Biotech Investor NEWS FLASH – THE DRUG AND BIOTECH REPORT We mentioned last night that we would be buyers of Biomira Inc. (BIOM) if the price approached $3. Biomira is a Canadian biotechnology company that is developing innovative approaches to cancer treatment and management. BIOM has a focus on developing synthetic vaccines and has a number of products in human trials. Theratope, a BIOM product for treatment of breast cancer patients, showed encouraging potential in Phase II clinical trials, in which mean survival time for Theratope treated patients was 28 months vs. 9 months for untreated control patients. It actually opened lower today at $2.44 and then rose to its current level as we write this at 2:30 PM ET, of $3. Thus, we hereby add Biomira to our NEW Drug and Biotech Portfolio at a price of $2 7/8. A note of caution: This is the first stock that we have ever recommended that is less than $5 in price. This is a micro-cap and has a market cap of less than $150 million. It is VERY SPECULATIVE, since the firm has virtually no revenues and may never have any, depending on how their drugs do in trials and in their approval process with the FDA. They lost $4 million last Q on revenues of less than $1 million but they do have $46 million in cash. For more details, see yesterday's Drug and Biotech Investor and note that we will be placing more details on the web site during the coming week. Our current price target is $4.25, a 48% increase if met. Good investing! Dr. Eddy Arnold Senior Contributing Editor The Drug and Biotech Investor BiotechInvestor@Bull-Market.com Todd Shaver Editor in Chief The Bull Market Report Washington, DC USA Todd@Bull-Market.com September 10, 1999 ______________________________________________________________________ To unsubscribe, write to BiotechInvestor-unsubscribe@listbot.com MSN Messenger Service lets you stay in touch instantly with your family & friends - Visit messenger.msn.com

To: WhatsUpWithThat who wrote (95346)	9/10/1999 2:56:00 PM
From: hoffy	Read Replies (1) \| Respond to of 119973

TCTY will be the next recent IPO to move. It's so undervalued here. A lot of big boys have an investment in TCTY.